Document Detail


Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
MedLine Citation:
PMID:  15605244     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thalidomide is an effective agent for patients with refractory multiple myeloma (MM) with a response rate of 30-40% at doses of 200-800 mg but with considerable side effects. We questioned whether lower doses of thalidomide in combination with a daily dose of cyclophosphamide might be an effective regimen with fewer side effects. We included 38 patients with relapsed or refractory MM. The median doses of thalidomide and cyclophosphamide were 100 and 95 mg/day, respectively. Side effects were observed in all patients, with neurotoxicity as the most troublesome. With a median follow-up of 14 months 84% of the patients responded, including 64% partial responses. The median time of progression-free survival was 30 months and the median overall survival time was 20 months. In conclusion, the results demonstrate that the combination of low-dose thalidomide with a daily dose of cyclophosphamide is an effective regimen with a high overall response rate and manageable side effects.
Authors:
Sjoerd Hovenga; Simon M G J Daenen; Joost T M de Wolf; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Wim J Sluiter; Edo Vellenga
Related Documents :
9132214 - Gym and tonic: a profile of 100 male steroid users.
8039154 - Dose intensity and high dose therapy. two different concepts.
15052614 - Clinical evaluation and management of myasthenia gravis.
24783934 - Autotetraploidy induced in nianmaohuangqin (radix scutellariae viscidulae) with colchic...
3689634 - Oral phenytoin pharmacokinetics during omeprazole therapy.
18580704 - Croup management in australia and new zealand: a predict study of physician practice an...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't     Date:  2004-12-17
Journal Detail:
Title:  Annals of hematology     Volume:  84     ISSN:  0939-5555     ISO Abbreviation:  Ann. Hematol.     Publication Date:  2005 May 
Date Detail:
Created Date:  2005-04-01     Completed Date:  2005-08-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  311-6     Citation Subset:  IM    
Affiliation:
Department of Haematology, University Hospital Groningen, P.O. Box 30.001, 9700, Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*,  toxicity
Cyclophosphamide / administration & dosage,  toxicity
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Humans
Immunosuppressive Agents / administration & dosage,  toxicity
Male
Multiple Myeloma / mortality,  prevention & control*
Recurrence
Thalidomide / administration & dosage,  toxicity
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 50-18-0/Cyclophosphamide; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential location of alpha-expansin proteins during the accommodation of root cells to an arbusc...
Next Document:  Gene expression profiles during beta cell maturation and after IL-1beta exposure reveal important ro...